EurekAlert! -
24 Jun 2021 06:00
(Beth Israel Deaconess Medical Center) Researchers report that about a quarter of localized prostate cancers may demonstrate immunologic traits that would allow a substantial number of patients with prostate cancer to benefit from immunotherapies.
Share this Article